RedHill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

RedHill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 120,500 shares, an increase of 455.3% from the August 15th total of 21,700 shares. Approximately 9.5% of the shares of the company are sold short. Based on an average daily trading volume, of 316,100 shares, the short-interest ratio is presently 0.4 days.

RedHill Biopharma Trading Up 2.5 %

NASDAQ:RDHL traded up $0.27 on Friday, hitting $11.01. The stock had a trading volume of 39,804 shares, compared to its average volume of 137,852. The business’s 50-day simple moving average is $9.60 and its two-hundred day simple moving average is $10.87. RedHill Biopharma has a 52-week low of $6.43 and a 52-week high of $82.00.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on RedHill Biopharma in a research note on Saturday, August 24th. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On RedHill Biopharma

A hedge fund recently raised its stake in RedHill Biopharma stock. Gagnon Securities LLC raised its holdings in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) by 32.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 118,360 shares of the biotechnology company’s stock after buying an additional 28,771 shares during the period. Gagnon Securities LLC owned about 0.40% of RedHill Biopharma worth $63,000 at the end of the most recent quarter. Institutional investors own 7.20% of the company’s stock.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.